Lixte Biotechnology (LIXTW) Competitors

$0.06

-0.01 (-13.74%)

(As of 07/25/2024 ET)

Stock Analysis Chart Competitors Financials SEC Filings Short Interest Trends

LIXTW vs. AEHAW, ALVOW, ACABW, SUBL, SAVAW, CMRAW, CGEN, FBIOP, MYNZ, and NLSPW

Should you be buying Lixte Biotechnology stock or one of its competitors? The main competitors of Lixte Biotechnology include Aesther Healthcare Acquisition (AEHAW), Alvotech (ALVOW), Atlantic Coastal Acquisition Corp. II (ACABW), BioLingus (Cayman) (SUBL), Cassava Sciences (SAVAW), Comera Life Sciences (CMRAW), Compugen (CGEN), Fortress Biotech (FBIOP), Mainz Biomed (MYNZ), and NLS Pharmaceutics (NLSPW). These companies are all part of the "pharmaceutical products" industry.

Lixte Biotechnology vs.

Lixte Biotechnology (NASDAQ:LIXTW) and Aesther Healthcare Acquisition (NASDAQ:AEHAW) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends, valuation and community ranking.

: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Lixte Biotechnology N/A N/A N/A N/A N/A
Aesther Healthcare Acquisition N/A N/A N/A N/A N/A
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lixte Biotechnology
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
N/A
Aesther Healthcare Acquisition
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
N/A
: Lixte Biotechnology and Aesther Healthcare Acquisition both received 0 outperform votes by MarketBeat users.
Company Underperform Outperform
Lixte Biotechnology N/A N/A
Aesther Healthcare Acquisition N/A N/A
: Company Net Margins Return on Equity Return on Assets
Lixte Biotechnology N/A N/A N/A
Aesther Healthcare Acquisition N/A N/A N/A
: In the previous week, Lixte Biotechnology had 1 more articles in the media than Aesther Healthcare Acquisition. MarketBeat recorded 1 mentions for Lixte Biotechnology and 0 mentions for Aesther Healthcare Acquisition. Lixte Biotechnology's average media sentiment score of 1.89 beat Aesther Healthcare Acquisition's score of 0.00 indicating that Lixte Biotechnology is being referred to more favorably in the media.
Company Overall Sentiment
Lixte Biotechnology Very Positive
Aesther Healthcare Acquisition Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lixte Biotechnology	N/A	N/A	N/A	N/A	N/A
Aesther Healthcare Acquisition	N/A	N/A	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lixte Biotechnology	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
Aesther Healthcare Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Company	Underperform	Outperform
Lixte Biotechnology	N/A	N/A
Aesther Healthcare Acquisition	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Lixte Biotechnology	N/A	N/A	N/A
Aesther Healthcare Acquisition	N/A	N/A	N/A

Company	Overall Sentiment
Lixte Biotechnology	Very Positive
Aesther Healthcare Acquisition	Neutral

Summary

Lixte Biotechnology beats Aesther Healthcare Acquisition on 2 of the 2 factors compared between the two stocks.

Ad Colonial Metals

Collapse of the Petrodollar

The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Russia, China and India have decided to abandon the petrodollar.

In answer to this issue, we have released a Special Report to the public.

Get Lixte Biotechnology News Delivered to You Automatically

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LIXTW vs. The Competition

Export to Excel

Metric	Lixte Biotechnology	Biotechnology Industry	Medical Sector	NASDAQ Exchange
Market Cap	N/A	$148.81M	$5.32B	$8.20B
Dividend Yield	N/A	3.49%	2.72%	3.97%
P/E Ratio	N/A	91.50	156.41	18.66
Price / Sales	N/A	17,674.37	2,081.06	91.54
Price / Cash	N/A	12.04	35.90	34.11
Price / Book	N/A	6.65	4.95	4.51
Net Income	N/A	-$19.78M	$112.29M	$216.36M
7 Day Performance	N/A	1.01%	2.73%	1.82%
1 Month Performance	N/A	6.12%	6.97%	7.09%
1 Year Performance	N/A	12.18%	11.22%	4.88%

Lixte Biotechnology Competitors List

Export to Excel

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AEHAW Aesther Healthcare Acquisition	0 of 5 stars 0.00 / 5 stars	$0.05 flat	N/A	-76.4%	$0.00	N/A	0.00	2	Gap Up
ALVOW Alvotech	0 of 5 stars 0.00 / 5 stars	$2.68 +7.6%	N/A	+70.4%	$0.00	$112.42M	0.00	4	Gap Up
ACABW Atlantic Coastal Acquisition Corp. II	0 of 5 stars 0.00 / 5 stars	$0.08 flat	N/A	N/A	$0.00	N/A	0.00	4	Positive News
SUBL BioLingus (Cayman)	0 of 5 stars 0.00 / 5 stars	N/A	N/A	N/A	$0.00	N/A	0.00	N/A	High Trading Volume
SAVAW Cassava Sciences	0 of 5 stars 0.00 / 5 stars	$0.03 flat	N/A	N/A	$0.00	N/A	0.00	30	Gap Up
CMRAW Comera Life Sciences	0 of 5 stars 0.00 / 5 stars	$0.00 flat	N/A	N/A	$0.00	$1.00M	0.00	2
CGEN Compugen	1.3123 of 5 stars 1.31 / 5 stars	$1.82 flat	$4.00 +119.8%	+60.9%	$0.00	$33.46M	-9.58	70
FBIOP Fortress Biotech	0 of 5 stars 0.00 / 5 stars	$8.03 -0.2%	N/A	-47.6%	$0.00	$85.11M	0.00	170	Short Interest ↓ News Coverage High Trading Volume
MYNZ Mainz Biomed	1.6469 of 5 stars 1.65 / 5 stars	$0.38 +8.5%	$6.00 +1,474.8%	-92.4%	$0.00	$900,000.00	-0.23	30	Short Interest ↑ News Coverage Gap Up
NLSPW NLS Pharmaceutics	0 of 5 stars 0.00 / 5 stars	$0.04 flat	N/A	-55.5%	$0.00	N/A	0.00	6	Short Interest ↑